DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
968
AMG-714
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
AMG-714
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GREMUBAMAB
2
Antibody
Investigational
Unknown
Unknown
Pneumonia
Low calcium response locus protein V inhibitor
GREMUBAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
3QG7W0YN2Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IPH-2101
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Multiple Myeloma
Killer cell immunoglobulin-like receptor 2DL1 inhibitor
IPH-2101
×
Maximum Phase:
2
First Approval:
None
UNII:
5Q686XLG8L
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MAVRILIMUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Giant Cell Arteritis; Severe Acute Respiratory Syndrome
Granulocyte-macrophage colony-stimulating factor receptor antagonist
MAVRILIMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1158JD1P9A
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GSK-249320
2
Antibody
Investigational
Unknown
Unknown
Stroke
Myelin-associated glycoprotein inhibitor
GSK-249320
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IERAMILIMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Melanoma; Triple Negative Breast Neoplasms
Lymphocyte activation gene 3 protein inhibitor
IERAMILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
OI8P0SFD4R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BEMARITUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Adenocarcinoma
Unknown
BEMARITUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
RJW23BQ0KW
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OZORALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
TNF-alpha inhibitor
OZORALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
05ZCK72TXZ
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUHMFG1
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms
Mucin-1 other
HUHMFG1
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ETOKIMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma; Dermatitis, Atopic; Peanut Hypersensitivity; Sinusitis
Interleukin-33 binding agent
ETOKIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
7UWT6B0L2U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDX-447
2
Antibody
Investigational
Unknown
Unknown
Central Nervous System Neoplasms
Epidermal growth factor receptor erbB1 cross-linking agent
MDX-447
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MLNM-2201
2
Antibody
Investigational
Unknown
Unknown
Unknown
Integrin beta-2 inhibitor
MLNM-2201
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MOR03087
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MOR03087
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ABELACIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
ABELACIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
KX1N4TV7UY
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDX-070
2
Antibody
Investigational
Unknown
Unknown
Unknown
Glutamate carboxypeptidase II other
MDX-070
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GSK-679586A
2
Antibody
Investigational
Unknown
Unknown
Asthma
Unknown
GSK-679586A
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AZ9773
2
Antibody
Investigational
Unknown
Unknown
Unknown
TNF-alpha inhibitor
AZ9773
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
M5A 90Y
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
M5A 90Y
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OMBURTAMAB
2
Antibody
Investigational
Unknown
Unknown
Medulloblastoma; Meningeal Carcinomatosis
Unknown
OMBURTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
XQL6783S5T
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BLOSOZUMAB
2
Antibody
Investigational
Unknown
Unknown
Osteoporosis, Postmenopausal; Osteoporosis
Sclerostin inhibitor
BLOSOZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
83YOM0NEL5
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
L19TNFA
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Fibronectin binding agent
L19TNFA
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CLIVATUZUMAB TETRAXETAN
2
Antibody
Investigational
Unknown
Unknown
Pancreatic Neoplasms
Mucin-5AC binding agent
CLIVATUZUMAB TETRAXETAN
×
Maximum Phase:
2
First Approval:
None
UNII:
1D1F7UG35J
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RINUCUMAB
2
Antibody
Investigational
Unknown
Unknown
Macular Degeneration
Platelet-derived growth factor receptor beta inhibitor
RINUCUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
10E3O6YI4W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NIMACIMAB
2
Antibody
Investigational
Unknown
Unknown
Gastroparesis
Cannabinoid CB1 receptor negative allosteric modulator
NIMACIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
85TS31SOL3
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UPANOVIMAB
2
Antibody
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Unknown
UPANOVIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BI-505
2
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma
Intercellular adhesion molecule-1 antagonist
BI-505
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DULIGOTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
DULIGOTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
8PMF8YQX2T
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVE-1642
2
Antibody
Investigational
Unknown
Unknown
Liver Neoplasms; Multiple Myeloma; Breast Neoplasms
Insulin-like growth factor I receptor antagonist
AVE-1642
×
Maximum Phase:
2
First Approval:
None
UNII:
Z9U2SS9ZC8
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VOBARILIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Erythematosus, Systemic
Interleukin-6 receptor alpha subunit inhibitor
VOBARILIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
9OD8ISS64U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DACETUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Lymphoma, Large B-Cell, Diffuse
Tumor necrosis factor receptor superfamily member 5 inhibitor
DACETUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
UT59FF4T5X
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
J591
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Unknown
J591
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GSK-1070806
2
Antibody
Investigational
Unknown
Unknown
Crohn Disease; Dermatitis, Atopic; Inflammatory Bowel Diseases; Behcet Syndrome; Diabetes Mellitus
Interleukin-18 inhibitor
GSK-1070806
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOL-101
2
Antibody
Investigational
Unknown
Unknown
Renal Insufficiency, Chronic
T-cell receptor inhibitor
TOL-101
×
Maximum Phase:
2
First Approval:
None
UNII:
28X0AGG6P8
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BL22
2
Antibody
Investigational
Unknown
Unknown
Lymphoma; Leukemia; Leukemia, Hairy Cell
CD22 binding agent
BL22
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TELISOTUZUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung
Hepatocyte growth factor receptor binding agent
TELISOTUZUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
976X9VXC3Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
16
17
18
19
20
21
22
…
27
28
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA